CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 456 enrolled
Drug / intervention
eszopiclone +2 moredrug
Likely dose
eszopiclone 1.5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00616655
NCT00616655Phase 2Completed
CompareCT.gov

A Double Blind, Randomized, Placebo Controlled, Multicenter Study Examining the Efficacy and Safety of SEP-225441 in Subjects With Generalized Anxiety Disorder.

Sumitomo Pharma America, Inc.·interventional·Posted Feb 15, 2008·Updated Apr 8, 2016

In Brief

A Phase 2 clinical trial evaluating eszopiclone and Placebo for Generalized Anxiety Disorder. Completed, enrolled 456 participants across 57 sites.

Detailed Summary

To determine the safety and efficacy of SEP-225441 (eszopiclone) in subjects with generalized anxiety disorder (GAD).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGeneralized Anxiety Disorder
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedFeb 15, 2008
Enrollment StartJan 1, 2008
Primary CompletionDec 1, 2008
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 18.4 years ago

Interventions

eszopiclonedrug

SEP-225441 (eszopiclone) total daily dose of 1.5 mg

eszopiclonedrug

SEP-225441 (eszopiclone) total daily dose of 0.9 mg

Placebodrug

Placebo total daily dose 0.9 mg